Akiyama, H.; Umezawa, Y.; Watanabe, D.; Okada, K.; Ishida, S.; Nogami, A.; Miura, O.
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells. Cancers 2020, 12, 406.
https://doi.org/10.3390/cancers12020406
AMA Style
Akiyama H, Umezawa Y, Watanabe D, Okada K, Ishida S, Nogami A, Miura O.
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells. Cancers. 2020; 12(2):406.
https://doi.org/10.3390/cancers12020406
Chicago/Turabian Style
Akiyama, Hiroki, Yoshihiro Umezawa, Daisuke Watanabe, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura.
2020. "Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells" Cancers 12, no. 2: 406.
https://doi.org/10.3390/cancers12020406
APA Style
Akiyama, H., Umezawa, Y., Watanabe, D., Okada, K., Ishida, S., Nogami, A., & Miura, O.
(2020). Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells. Cancers, 12(2), 406.
https://doi.org/10.3390/cancers12020406